Skip to content

Botulinum Toxin Type A Assisted with High-density Adipose Transplantation for Raynaud's Syndrome

Clinical observation of high-density adipose combined with botulinum toxin type A in the treatment of Raynaud's Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057580
Enrollment
Unknown
Registered
2022-03-15
Start date
2022-03-20
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Raynaud's Syndrome

Interventions

Group 1:Botulinum Toxin Type A Assisted with High-density Adipose
Group 2:Botulinum Toxin Type A

Sponsors

Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-70 years; 2. Various primary or secondary Raynaud's syndrome.

Exclusion criteria

Exclusion criteria: 1. Those with severe vital organ pathology that cannot tolerate surgery; 2. Patients with diseases of the hematopoietic system or immune system; 3. Patients with allergies, scarring, or abnormal constitution; 4. Patients with combined severe mental disorders or severe cognitive dysfunction are not allowed to undergo surgery; 5. Patients who are pregnant and lactating, menstruating, or preparing for pregnancy; 6. Patients with infected lesions in the affected area; 7. Patients whose family members do not agree to the surgery; 8. Patients who are taking drugs that affect neuromuscular transmission; 9. Combined venous reflux disorders.

Design outcomes

Primary

MeasureTime frame
Infrared thermography;Degree of finger pain, numbness, stiffness;Blood oxygen saturation;Changes in finger ulcers ;

Secondary

MeasureTime frame
McCabe score;

Countries

China

Contacts

Public ContactChengliang Deng

Affiliated Hospital of Zunyi Medical University

cheliadeng@sina.com+86 15085115296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026